Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures

Transfusion

Volumn 43, Issue 3, 2003, Pages 390-394

  Konkle, Barbara A ^a   Bauer, Kenneth A ^b   Weinstein, Robert ^b   Greist, Anne ^b   Holmes, Houston E ^b   Bonfiglio, Judith ^b  

^a PMC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBIN; RECOMBINANT ANTITHROMBIN; RECOMBINANT ANTITHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; ARTICLE; BLEEDING; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERPIGMENTATION; MALE; PERIOPERATIVE PERIOD; THROMBOEMBOLISM; THROMBOSIS; TRANSGENIC ANIMAL; VEIN THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; ANTITHROMBINS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CESAREAN SECTION; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENOXAPARIN; FACTOR V; FEMALE; HEPARIN; HUMANS; HYSTERECTOMY; LEIOMYOMA; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREGNANCY; RECOMBINANT PROTEINS; SPLENECTOMY; STERILIZATION, TUBAL; SURGICAL PROCEDURES, OPERATIVE; UTERINE NEOPLASMS; VENOUS THROMBOSIS; WARFARIN;

EID: 0037343212     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00315.x     Document Type: Article

References (15)

1. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin III deficient persons. Report of a large kindred and literature review. Ann Int Med 1992;116:754-61.
2. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose-und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996;16:742-8.
3. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia. Part 1. Thromb Haemost 1996;76:651-2.
4. Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin. Structural and functional comparison to human plasma-derived antithrombin. Blood 1998;91:4561-71.
5. Lu W, Mant T, Levy JH, Bailey JM. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg 2000;90:531-4.
6. Menache D, O'Malley JP, Schorr JB, Wagner B, Williams C. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990;75:33-9.
7. Lechner K, Kyrle PA. Antithrombin III concentrates - Are they clinically useful? Thromb Haemost 1995;73:340-8.
8. De Swart CA, Nijmeyer B, Andersson LO, et al. Elimination of intravenously administered radiolabelled anti-thrombin III and heparin in humans. Thromb Haemost 1984;52:66-70.
9. Knot EA, de Jong E, ten Cate JW, Gie LK, van Royen EA, Antithrombin III. Biodistribution in healthy volunteers. Thromb Haemost 1987;58:1008-11.
10. Collen D, Schetz J, de Cock F, Holmer E, Verstraete M. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest 1977;7:27-35.
11. Knot EA, de Jong E, ten Cate JW, et al. Purified radiolabeled antithrombin III metabolism in three families with hereditary AT III deficiency. Application of a three-compartment model. Blood 1986;67:93-8.
12. Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience in antithrombin III concentrate in treatment of congenital and acquired deficiency of anlithrombin. Am J Med 1989;87(Suppl 3B):53S-60S.
13. Soucie JM, Erdman DD, Evatt BL, et al. Investigation of porcine parvovirus among persons with hemophilia receiving Hyate-C porcine factor VIII concentrate. Transfusion 2000;40:708-11.
14. Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998;26:89-94.
15. van Elsacker-Niele AM, Kroes AC. Human parvovirus B19: relevance in internal medicine. Neth J Med 1999;54:221-30.